Interferon in hepatitis B;Interferón en la hepatitis B

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 7, 2008, Pages 19-31

  Buey, Luisa García ^a   Mateos, Fernando González ^b   Oteroa, Ricardo Moreno ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Chronic hepatitis HBV (CHB); Hepatitis B virus (HBV); Hepatitis B virus genotypes; Interferon (IFN ); Pegylated interferon (PEG IFN ); Sustained response

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PREDNISONE; TELBIVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHEMOTHERAPY; CHRONIC HEPATITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; INFECTION RATE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MORTALITY; NONHUMAN; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 75149128280     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76516-9     Document Type: Article

References (71)

1. D. Ganem, and A.M. Prince Hepatitis B virus infection:natural history and clinical consequences N Engl J Med 350 2004 1118 1129 (Pubitemid 38298992)
2. C.L. Lai, V. Ratziu, M.F. Yuen, and T. Poynard Viral hepatitis B Lancet 362 2003 2089 2094 (Pubitemid 38032767)
3. J.H. Hoofnagle, E. Doo, T.J. Liang, R. Fleischer, and A.S. Lok Management of hepatitis B: summary of a clinical research workshop Hepatology 45 2007 1056 1075 (Pubitemid 46646501)
4. A.S. Lok, and B.J. McMahon AASLD Practice Guidelines. Chronic hepatitis B Hepatology 45 2007 507 539
5. The EASL Jury EASL International consensus conference on hepatitis B 13-14 September 2002. Geneva, Switzerland. Consensus statement J Hepatol 38 2003 533 540 (Pubitemid 36399261)
6. Y.F. Liaw, N. Leung, R. Guan, G.K. Lau, I. Merican, G. McCaughan, et al. Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update Liver Int 25 2005 472 489
7. E.B. Keeffe, D.T. Dieterich, S.H. Han, I.M. Jacobson, P. Martin, and E.R. Schiff A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update Clin Gastroenterol Hepatol 4 2006 936 962 (Pubitemid 44118844)
8. G.C. Farrell, and N.C. Teoh Management of chronic hepatitis B virus infection: a new era of disease control Intern Med J 36 2006 100 113 (Pubitemid 43287322)
9. R.G. Gish Clinical trial results of new therapies for HBV: implications for treatment guidelines Semin Liver Dis 25 Suppl 1 2005 29 39
10. R.P. Perrillo Current treatment of chronic hepatitis B: benefits and limitations Semin Liver Dis 25 Suppl 1 2005 20 28 (Pubitemid 41254590)
11. W.G. Cooksley Treatment with interferons (including pegylated interferons) in patients with hepatitis B Semin Liver Dis 24 Suppl 1 2004 45 53 (Pubitemid 38738358)
12. G.W. Robins, L.J. Scott, and G.M. Keating Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B Drugs 65 2005 809 825 (Pubitemid 40598094)
13. A. Isaacs, and J. Lindenmann Virus interference. I. The interferon J Interferon Res 7 1987 429 438
14. H.B. Greenberg, R.B. Pollard, L.I. Lutwick, P.B. Gregory, W.S. Robinson, and T.C. Merigan Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis N Engl J Med 295 1976 517 522
15. Ch.E. Samuel Antiviral actions of interferons Clin Microbiol Rev 14 2001 778 809
16. J.U. Gutterman Cytokine therapeutics: lessons from interferon alpha Proc Natl Acad Sci USA 91 1994 1198 1205
17. S. Goodbourn, L. Didcock, and R.E. Randall Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures J Gen Virol 81 2000 2341 2364 (Pubitemid 30738383)
18. G.R. Stark, I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber How cells respond to interferons Annu Rev Biochem 67 1998 227 264
19. D.L. Brassard, M.J. Grace, and R.W. Bordens Interferon-alpha as an immunotherapeutic protein J Leukoc Biol 71 2002 565 581
20. A. Craxi, and W.G. Cooksley Pegylated interferons for chronic hepatitis B Antiviral Res 60 2003 87 89 (Pubitemid 37452451)
21. W.G.E. Cooksley, T. Piratvisuth, S.D. Lee, V. Mahachai, Y.C. Chao, and T. Tanwandee Pegynterferon a-2a (40 KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 2003 298 305 (Pubitemid 36801917)
22. R. Perrillo, C. Tamburro, F. Regenstein, L. Balart, H. Bodenheimer, M. Silva, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus Gastroenterol 109 1995 908 916
23. J.H. Hoofnagle, A.M. Di Bisceglie, J.G. Waggoner, and Y. Park Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B Gastroenterol 104 1993 1116 1121 (Pubitemid 23090765)
24. E.H. Buster, B.E. Hansen, M. Buti, J. Delwaide, C. Niederau, P.P. Michielsen HBV 99-01 Study Group Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis Hepatology 46 2007 388 394 (Pubitemid 47344773)
25. M. Van Zonneveld, P. Honkoop, B.E. Hansen, H.G. Niesters, S.D. Murad, and R.A. De Man Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 2004 804 810 (Pubitemid 38337661)
26. H.L. Janssen, G. Gerken, V. Carreno, P. Marcellin, N.V. Naoumov, A. Craxi, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 30 1999 238 243
27. P. Lampertico, E. Del Ninno, M. Viganò, R. Romeo, M.F. Donato, and E. Sablon Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 2003 756 763 (Pubitemid 36397385)
28. H.L. Chan, N.W. Leung, A.Y. Hui, V.W. Wong, C.T. Liew, and A.M. Chim A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha 2b and lamivudine with lamivudine alone Ann Intern Med 142 2005 240 250 (Pubitemid 40216241)
29. J.B. Wong, R.S. Koff, F. Tine, and S.G. Pauker Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B Ann Intern Med 122 1995 664 675
30. Almasio P, Camma C, Giunta M, Craxi A. treatment of chronic hepatitis B: an evidence-based review. En: McDonald JWD, Borroughs A, Feagan BG, editors. Evidence-based gastroenterology and hepatology. London: BMJ Publications. 1999. p: 305-21.
31. F. Tine, A. Liberati, A. Craxi, P. Almasio, and L. Pagliaro Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature J Hepatol 18 1993 154 162 (Pubitemid 23246941)
32. D.K. Wong, A.M. Cheung, K. O'Rourke, C.D. Naylor, A.S. Detsky, and J. Heathcote Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 1993 312 323 (Pubitemid 23319890)
33. A. Craxi, D. Di Bona, and C. Camma Interferon-alpha for HBeAg-positive chronic hepatitis B J Hepatol 39 Suppl 1 2003 S99 S105
34. D.T. Lau, J. Everhart, D.E. Kleiner, Y. Park, J. Vergalla, and P. Schmid Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa Gastroenterology 113 1997 1660 1667 (Pubitemid 27461254)
35. S.M. Lin, I.S. Sheen, R.N. Chien, C.M. Chu, and Y.F. Liaw Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 1999 971 975 (Pubitemid 29109617)
36. J. Korenman, B. Baker, J. Waggoner, J.E. Everhart, A.M. Di Bisceglie, and J.H. Hoofnagle Long-term remission of chronic hepatitis B after alpha-interferon therapy Ann Intern Med 114 1991 629 634
37. Y.S. Hsu, R.N. Chien, C.T. Yeh, I.S. Sheen, H.Y. Chiou, and C.M. Chu Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527 (Pubitemid 34966908)
38. E.M. Sokal, H.S. Conjeevaram, E.A. Roberts, F. Alvarez, E.M. Bern, and P. Goyens Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial Gastroenterol 114 1998 988 995 (Pubitemid 28217565)
39. P. Jara, and F. Bortolotti Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children J Pediatr Gastroenterol Nutr 29 1999 163 170 (Pubitemid 30366166)
40. D. Torre, and R. Tambini Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis Clin Infect Dis 23 1996 131 137 (Pubitemid 26323808)
41. L. D'Antiga, M. Aw, M. Atkins, A. Moorat, D. Vergani, and G. Mieli-Vergani Combined lamivudine/interferon-alpha treatment in «immunotolerant» children perinatally infected with hepatitis B: a pilot study J Pediatr 148 2006 228 233 (Pubitemid 43286766)
42. G. Fattovich, G. Giustina, J. Sanchez-Tapias, C. Quero, A. Mas, P.G. Olivotto, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol 93 1998 896 900
43. C. Niederau, T. Heintges, S. Lange, G. Goldmann, C.M. Niederau, and L. Mohr Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427 (Pubitemid 26157437)
44. M.R. Brunetto, F. Oliveri, B. Coco, G. Leandro, P. Colombatto, and J.M. Gorin Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study J Hepatol 36 2002 263 270 (Pubitemid 34146434)
45. G.V. Papatheodoridis, E. Manesis, and S.J. Hadziyannis The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313 (Pubitemid 32176454)
46. F. Oliveri, T. Santantonio, G. Bellati, P. Colombatto, G.C. Mels, and L. Carriero Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon Am J Gastroenterol 94 1999 1366 1372 (Pubitemid 29214655)
47. F. González-Mateos, C. García-Monzón, L. García-Buey, A. García-Sánchez, J.M. Pajares, and R. Moreno-Otero Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature Hepatogastroenterol 42 1995 893 899 (Pubitemid 26026452)
48. M. Cohard, T. Poynard, P. Mathurin, and J.P. Zarski Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis Hepatology 20 1994 1390 1398 (Pubitemid 24359046)
49. S.W. Schalm, J. Heathcote, J. Cianciara, G. Farrell, M. Sherman, and B. Willems Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial Gut 46 2000 562 568 (Pubitemid 30305823)
50. G. Barbaro, F. Zechini, A.M. Pellicelli, R. Francavilla, G. Scotto, D. Bacca Lamivudine Italian Study Group Investigators Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial J Hepatol 35 2001 406 411 (Pubitemid 32844196)
51. T. Sanantonio, G.A. Niro, and E. Sinisi Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study J Hepatol 36 2002 799 804 (Pubitemid 35177410)
52. H.L. Janssen, S.W. Schalm, L. Berk, R.A. De Man, and R.A. Heijtink Repeated courses of alpha-interferon for treatment of chronic hepatitis type B J Hepatol 17 Suppl 3 1993 S47 S51 (Pubitemid 23114342)
53. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695 (Pubitemid 41007823)
54. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217 (Pubitemid 39296307)
55. A.Y. Hui, H.L. Chan, A.Y. Cheung, G. Cooksley, and J.J. Sung Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon Aliment Pharmacol Ther 22 2005 519 528 (Pubitemid 41360798)
56. H.L. Chan, A.Y. Hui, V.W. Wong, A.M. Chim, M.L. Wong, and J.J. Sung Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B Hepatology 41 2005 1357 1364 (Pubitemid 40770289)
57. H.L. Janssen, M. Van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, Y. Cakaloglu HBV 99-01 Study Group; Rotterdam Foundation for Liver Research Pegylated interferon alfa-2b alone or in combination with lamivudine for HBe-Ag-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129 (Pubitemid 40091801)
58. M. Van Zonneveld, P.E. Zondervan, Y. Cakaloglu, C. Simon, U.S. Akarca, T.M. So, et al. HBV 99-01 Study Group Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine Liver Int 26 2006 399 405
59. H.J. Flink, B.E. Hansen, E.J. Heathcote, S.V. Feinman, H. Simsek, S. Karayalcin HBV 99-01 Study Group Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine Am J Gastroenterol 101 2006 2523 2529 (Pubitemid 44665248)
60. W.F. Leemans, H.J. Flink, H.L. Janssen, H.G. Niesters, S.W. Schalm, and R.A. De Man The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection J Hepatol 44 2006 507 511
61. S. Kaymakoglu, D. Oguz, G. Gur, S. Gurel, E. Tankurt, and G. Ersöz Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B Antimicrob Agents Chemother 51 2007 3020 3022 (Pubitemid 47206252)
62. S.K. Sarin, A. Sood, M. Kumar, A. Arora, D. Amrapurkar, B.C. Sharma National Collaborative Group on Hepatitis B, India Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B Am J Gastroenterol 102 2007 96 104 (Pubitemid 46072048)
63. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, and B. Zollner Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 2006 675 684 (Pubitemid 44433724)
64. J.M. Sánchez-Tapias, J. Costa, A. Mas, M. Bruguera, and J. Rodés Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients Gastroenterology 123 2002 1848 1856 (Pubitemid 35408309)
65. J.H. Kao, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B Gastroenterology 118 2000 554 559 (Pubitemid 30140853)
66. C.T. Wai, C.J. Chu, M. Hussain, and A.S. Lok HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C Hepatology 36 2002 1425 1430 (Pubitemid 35403533)
67. S.K. Fung, and A.S. Lok Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40 2004 790 792
68. M. Enomoto, A. Tamori, and S. Nishiguchi Hepatitis B virus genotypes and response to antiviral therapy Clin Lab 52 2006 43 47 (Pubitemid 43245864)
69. A. Erhardt, D. Blondin, K. Hauck, A. Sagir, T. Kohnle, and T. Heintges Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D Gut 54 2005 1009 1013 (Pubitemid 40873918)
70. H.J. Flink, M. Van Zonneveld, B.E. Hansen, R.A. De Man, S.W. Schalm, H.L. Janssen HBV 99-01 Study Group Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype Am J Gastroenterol 101 2006 297 303 (Pubitemid 43381671)
71. M.J. Ter Borg, M. Van Zonneveld, S. Zeuzem, H. Senturk, U.S. Akarca, C. Simon HBV 99-01 Study Group Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response Hepatology 44 2006 721 727 (Pubitemid 44433729)